HomeReForm Biologics

ReForm Biologics

ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics

“Many antibody-based therapeutics need to be delivered intravenously due to their high dose requirements and viscosity in solution. Subcutaneous injection of a highly concentrated antibody solution is a preferred route for patients that require frequent and longer...